Physician profile
Shrinivas Bishu
NPI 1700010063
$38,911.97
in general payments reported to CMS, 2019-2025
6 companies · $21K in 2025
The $21K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.92 · 2020: $15.66 · 2021: $239 · 2022: $79.27 · 2023: $2,990 · 2024: $15K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $3,119 · Food and Beverage: $1,732 · Education: $67.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,165.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,475.00 |
| Travel and Lodging | $3,119.12 |
| Food and Beverage | $1,731.79 |
| Education | $67.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $20,588.23 | 2024-2025 | Tremfya, Stelara |
| Janssen Global Services, LLC | $7,520.29 | 2024 | Tremfya |
| Abbvie INC. | $5,957.83 | 2019-2025 | Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $4,427.50 | 2023-2024 | |
| Celgene Corporation | $269.04 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.08 | 2023-2024 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shrinivas Bishu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.